Kyverna Therapeutics appoints Marc Grasso as CFO; Ryan Jones moves to advisor

Kyverna Therapeutics, Inc.

Dr. Marc Grasso appointed CFO effective June 30, 2025; previously CFO of Alector (ALEC) and Kura Oncology (KURA).
Outgoing CFO Ryan Jones will serve as strategic advisor through August 8, 2025; receives severance including 9 months salary and continued vesting.
Grasso receives base salary of $510,000, sign-on bonus of $250,000, and option for 450,000 shares vesting over four years.
Grasso brings over 25 years of experience in public company finance and biotech investment banking.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.